Q1 Earnings Forecast for BHST Issued By Diamond Equity

BioHarvest Sciences Inc. (NASDAQ:BHST) – Analysts at Diamond Equity issued their Q1 2026 earnings estimates for BioHarvest Sciences in a research report issued to clients and investors on Thursday, April 3rd. Diamond Equity analyst H. Diamond expects that the company will post earnings per share of ($0.01) for the quarter. The consensus estimate for BioHarvest Sciences’ current full-year earnings is ($0.80) per share. Diamond Equity also issued estimates for BioHarvest Sciences’ Q2 2026 earnings at $0.01 EPS, Q3 2026 earnings at $0.03 EPS and Q4 2026 earnings at $0.06 EPS.

Separately, Maxim Group assumed coverage on shares of BioHarvest Sciences in a report on Wednesday, December 18th. They issued a “buy” rating and a $12.00 target price for the company.

BioHarvest Sciences Stock Up 1.1 %

NASDAQ:BHST opened at $5.60 on Monday. BioHarvest Sciences has a twelve month low of $5.60 and a twelve month high of $7.38. The company has a 50-day simple moving average of $5.70. The firm has a market capitalization of $91.98 million, a price-to-earnings ratio of -4.48 and a beta of 0.84.

BioHarvest Sciences (NASDAQ:BHST) last issued its quarterly earnings results on Monday, March 31st. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.05). The firm had revenue of $7.17 million during the quarter, compared to the consensus estimate of $7.24 million.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in BioHarvest Sciences stock. TD Waterhouse Canada Inc. acquired a new stake in shares of BioHarvest Sciences Inc. (NASDAQ:BHST) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 12,042 shares of the company’s stock, valued at approximately $69,000. TD Waterhouse Canada Inc. owned approximately 0.07% of BioHarvest Sciences as of its most recent SEC filing.

BioHarvest Sciences Company Profile

BioHarvest Sciences Inc is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications.